Benzimidazole derivatives, their production and use

Details Benzimidazole derivatives, their production and use Benzimidazole derivatives, their production and use

1999-08-18

2001-05-15

Oswecki, Jane C. (Department: 1609)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S382000, C514S397000, C514S398000, C514S399000, C514S400000, C548S251000, C548S252000, C548S253000, C548S304700, C548S306100

Reexamination Certificate

active

06232334

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to novel benzimidazole derivatives having potent pharmacological actions and intermediates for the preparation thereof. More particularly, the present invention relates to compounds having potent anti-hypertensive activity and strong angiotensin II antagonistic activity, which are useful as therapeutic agents for treating circulatory diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
BACKGROUND OF THE INVENTION
The renin-angiotensin system is involved in the homeostatic function to control systemic blood pressure, the volume of body fluid, balance among the electrolytes, etc., associated with the aldosterone system. Development of angiotensin II converting enzyme inhibitors (ACE inhibitor) (this converting enzyme produces angiotensin II which possesses a strong vasoconstrictive action) has clarified the relation between the renin-angiotensin system and hypertension. Since angiotensin II constricts blood vessel to elevate blood pressure via the angiotensin II receptors on the cellular membranes, angiotensin II antagonists, like the ACE inhibitor, wouLd be useful in treating hypertension caused by angiotensin.
It has been reported that various angiotensin II analogues such as saralasin, [Sar
1
,Ile
8
]A II, and the like, possess potent angiotensin II antagonist activity.
It has, however, been reported that, when peptide antagonists are administered parenterally, their actions are not prolonged and, when administered orally, they are ineffective (M. A. Ondetti and D. W. Cushman, Annual Reports in Medicinal Chemistry, 13, 82-91 (1978)).
It would be highly desirable to develop a non-peptide angiotensin II antagonist which overcomes these drawbacks. In the eariest studies in this field, imidazole derivatives having angiotensin II antagonist activity have been disclosed in Japanese Patent Laid Open No. 71073/1981; No. 71074/1981; No. 92270/1982; No. 157768/1983; U.S. Pat. Nos. 4,355,040, 4,355,040, etc. Later, improved imidazole derivatives are disclosed in European Patent Laid Open No. 0253310, No. 0291969, No. 0324377, Japanese Patent Laid Open No. 23868/1988; and No. 117876/1989. Further, pyrole, pyrazole, and triazole derivatives are disclosed as angiotensin II antagonists in European Patent Laid Open No. 0323841, and Japanese Patent Laid Open No. 287071/1989.
U.S. Pat. No. 4,880,804 discloses benzimidazole derivatives having an angiotensin II receptor antagonistic action, which are intravenously active in vivo in rats with renal hypertension. Examples of such benzimidazole derivatives are those represented by the following formula (A):
wherein substituents, for example, in the 5- and/or 6-position are hydroxymethyl, methoxy, formyl, chloro, or carboxy. Although most compounds among those exemplified are orally inactive, it is said that only the 6-hydroxymethyl and 6-chloro compounds are orally effective (100 mg/kg or less). It is, however, believed that the activity of even these disclosed compounds is insufficient for clinical uses.
SUMMARY OF THE INVENTION
The present invention provides novel benzimidazole derivatives having potent anti-hypertensive activity and strong angiotensin II antagonistic action, which are of practical value in clinical use as therapeutic agents.
The present inventors considered that compounds functioning to control the renin-angiotensin system as well as clinically useful for the treatment of circulatory diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, etc. are required to have potent angiotensin II receptor antagonistic activity and to exert strong oral and long-lasting angiotensin II antagonist action. Extensive investigations were made based on those consideration. As a result of this research, the present inventors have succeeded in synthesizing novel 2-substituted benzimidazole derivatives (I) possessing highly angiotensin II receptor antagonistic activity as well as exerting strong oral and long-lasting angiotensin II antagonistic and anti-hypertensive action and developed the present invention.
The present invention relates to benzimidazole derivatives having the formula I:
wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R
1
is hydrogen or an optionally substituted hydrocarbon residue; R
2
is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O)
m
— or —N(R
4
)— wherein m is an integer of 0, 1 or 2 and R
4
is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof.
These compounds are unexpectedly potent angiotensin II antagonists which are of value in the treatment of circulatory system diseases such as hypertensive diseases, heart diseases, strokes, nephritis, etc.
Another aspect of the present invention relates to pharmaceutical compositions comprising an effective amount of the benzimidazole derivative having the formula I and a pharmaceutically acceptable carrier useful in treating circulatory system diseases such as hypertensive diseases, heart diseases, strokes, renal failure, nephritis, etc., and processes for preparing such compounds and compositions.
Still another aspect of the present invention relates to a method for treating said circulatory system diseases of animals, which comprises administering an effective amount of the benzimidazole derivatives having the formula I or the pharmaceutical composition thereof to said animal.


REFERENCES:
patent: 4526896 (1985-07-01), Schevral et al.
patent: 4764623 (1988-08-01), Kees
patent: 4775679 (1988-10-01), Chang
patent: 4880804 (1989-11-01), Carini et al.
patent: 5864043 (1999-01-01), Narr et al.
patent: 28833 (1981-05-01), None
patent: 28834 (1981-05-01), None
patent: 245637 (1987-11-01), None
patent: 253310 (1988-01-01), None
patent: 291969 (1988-11-01), None
patent: 323841 (1989-07-01), None
patent: 392317 (1990-10-01), None
patent: 399732 (1990-11-01), None
patent: 400835 (1990-12-01), None
patent: 420237 (1991-04-01), None
Noda et al., “Inhibition of Rabbit Aortic Angiotensin II (All) Receptor by CU-11974, A New Nonpeptide All Antagonist”, Biochem Pharm, vol. 46, No. 2, pp. 311-318 (1993).

Affiliated with

Also associated with

Rating

Benzimidazole derivatives, their production and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzimidazole derivatives, their production and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole derivatives, their production and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2454337